Trials / Not Yet Recruiting
Not Yet RecruitingNCT04965831
Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
Furmonertinib Mesylate as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable, EGFR Sensitizing Mutation Positive Lung Adenocarcinoma Patients: A Phase II, Single-arm, Open-label Clinical Study (FRONT)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC patients.
Detailed description
Please refer to detailed description in the following context.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Furmonertinib | Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery. |
Timeline
- Start date
- 2021-08-01
- Primary completion
- 2023-03-01
- Completion
- 2026-05-01
- First posted
- 2021-07-16
- Last updated
- 2021-07-16
Source: ClinicalTrials.gov record NCT04965831. Inclusion in this directory is not an endorsement.